Key result
In silico simulations demonstrated that combinations of high- and intermediate-risk drugs often yielded lower qNetavg than individual drugs, indicating increased torsade de pointes risk.
Why the study?
Most CiPA studies evaluate single-drug torsade de pointes risk, but two-drug fixed-dose combination therapy is widely used in cardiovascular disease management.
Does two-drug fixed-dose combination therapy alter the risk of Torsade de pointes compared to single-drug therapy in an in silico human ventricular cell model?
Does two-drug fixed-dose combination therapy alter the risk of Torsade de pointes compared to single-drug therapy in an in silico human ventricular cell model?
In silico CiPA-based modeling reveals that two-drug combinations can nonlinearly alter Torsade de pointes risk compared to single drugs, emphasizing the need for specific cardiotoxicity evaluation of fixed-dose combinations.
Certain drug combinations may increase TdP risk beyond monotherapy; leaves open whether CiPA modeling should inform fixed-dose combination evaluation.
The Comprehensive In Vitro Proarrhythmia Assay (CiPA) evaluates drug-induced torsade de pointes (TdP) risk, with qNet commonly used to classify drugs into low-, intermediate-, and high-risk categories.While most studies focus on single-drug effects, 2-drug fixed-dose combination (FDC) therapy is widely used for cardiovascular disease management.We aimed to develop the CiPA-based methodology to predict adverse effects of FDC therapy.A human ventricular cell model was stimulated under the effects of various drug combinations from twelve well-characterized compounds suggested by CiPA at 1 to 4 maximum plasma concentration, and the qNet avg biomarker as a function of the ratio of two drugs was used to evaluate the TdP risk of combined compounds.Results showed that high-risk and intermediate-risk drug combinations often yielded lower qNet avg than individual drugs, suggesting increased TdP risk.Conversely, combinations involving low-risk drugs tended to reduce TdP risk by raising qNet avg above individual drug levels.Also, we found that the interplay of some major ionic channels caused variations on qNet avg .These findings highlight the importance of evaluating FDC cardiotoxicity to predict risks that may not appear in single-drug analysis.
No takes yet. Share an insight, caveat, or question.
Qauli et al. (2024) studied Cardiotoxicity (Torsade de pointes risk). Two-drug fixed-dose combinations vs. Single-drug administration was evaluated on qNetavg biomarker for TdP risk classification. In silico simulations demonstrated that combinations of high- and intermediate-risk drugs often yielded lower qNetavg than individual drugs, indicating increased torsade de pointes risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: